6 mars 2026 Sweden
BioStock : Deep dive into Diamyd Medical ahead of crucial interim analysis
In a studio interview published by BioStock, Diamyd Medical CEO Ulf Hannelius, board member Professor Mark Atkinson, and Senior Director Joshua Vieth from the patient organisation Breakthrough T1D, discuss the current status of Diamyd Medical ahead of the upcoming march interim analysis of the pivotal Phase 3 DIAGNODE-3 trial. The discussion highlights the company’s antigen-specific immunotherapy being evaluated to preserve patients’ own insulin production in type 1 diabetes, as well as the clinical importance of maintaining endogenous insulin production for improved glucose control and long-term health outcomes.
Watch the full discussion here
Information som presenteras här är inte pressmeddelanden och kan innehålla utdrag ur och länkar till externt publicerat innehåll. Diamyd Medical ansvarar inte för externt publicerat innehåll.